Company news
SciSparc Ltd. news in 2022
SciSparc Ltd.'s news releases, calls and decks from 2022, newest first.
SciSparc Enters Into Non-Binding Letter of Intent to Sell a 50% interest in its Subsidiary that Owns an Amazon Top Seller Brand
December 13, 2022
SciSparc Announces Positive Study Results with SCI-210, a Cannabidiol-Based Treatment for Epilepsy
December 6, 2022
SciSparc Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
November 28, 2022
SciSparc Enters Into Letter of Intent with an E-commerce Company to Establish a Joint Venture to Market and Develop a New Product Line
November 14, 2022
SciSparc Gains Competitive Edge with Additional U.S. Patent Granted
November 7, 2022
SciSparc Announced Positive Interim Results Meeting Primary Endpoints at Phase IIa Study in Alzheimer’s Disease Patients with Agitation
November 6, 2022
SciSparc: Wellution™ Successfully Launched a New Keto Gummies Apple Cider Vinegar Product and Generated $100,000 In Revenues Within 30 Days
October 27, 2022
SciSparc Completes the Acquisition of Wellution™, Top Seller of American Food Supplements and Cosmetics Brand on Amazon, for $20 million
September 29, 2022
SciSparc Enters Agreement to Acquire Wellution™, Top Seller of American Food Supplements and Cosmetics Brand on Amazon, for $20 million
September 13, 2022
SciSparc Ltd. Announces Additional Positive Results for the Cocaine Addiction Treatment of its Psychedelic-based Pharma Collaboration with Clearmind Medicine Inc.
August 23, 2022
Scisparc Announces the Full Exercise of Pre-Funded Warrants
August 18, 2022
SciSparc will Deposit $1 million in Escrow for its Intention to Enter Into an Agreement to Acquire American Food Supplements and Cosmetics Brand
August 17, 2022
SciSparc Signs a Non- Binding Letter of Intent to Acquire American Food Supplements and Cosmetics Brand in Approximately $20 Million Deal
August 14, 2022
SciSparc Issued Israeli Patent for its Core Technology for Treating Central Nervous Systems Disorders
August 11, 2022
SciSparc Announces Israeli Ministry of Health Approval to Conduct its Clinical Trial in Autism Spectrum Disorder
August 7, 2022
SciSparc Signs Clinical Trial Agreement with Yale University to Conduct its Phase IIb Trial in Tourette Syndrome
July 31, 2022
SciSparc Announces Expanding its Clinical Operations to Include a U.S. Site Towards its Phase IIb Trial with its Proprietary SCI-110 for the Treatment of Tourette Syndrome
July 7, 2022
SciSparc's JV MitoCareX Bio Launches its Advanced New Laboratory Facility
July 6, 2022
SciSparc Board of Directors to Promote Buyback Program of up to $1 Million
July 5, 2022
SciSparc Successfully Completed The Development of its Proprietary Drug Candidate SCI-110 for its Upcoming Phase IIb Study In Tourette Syndrome
June 28, 2022
SciSparc Announces Ethics Committee Approval to Conduct its Clinical Trial in Autism Spectrum Disorder
June 22, 2022
SciSparc Reinforces its New JV for Targeting Discovery with a Global Expert in the Field of Mitochondrial Transport Proteins
June 14, 2022
SciSparc's Board of Directors Provides Strategic Decision
June 8, 2022
SciSparc Ltd. Announces Closing of $10 Million Private Placement Priced At-the-Market
May 31, 2022
SciSparc Announces Pricing of $10 Million Private Placement Priced At-the-Market
May 26, 2022
SciSparc Announces Ethics Committee Approval to Conduct a Phase IIb Trial in Tourette Syndrome
May 25, 2022
SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Yields New Patent Application for Psychedelic Combination Treatment for Binge Behaviors
May 9, 2022
SciSparc Files Annual Report for Year Ended December 31, 2021 and Provides Corporate Update
May 1, 2022
SciSparc Announces Closing of New JV Targeting Discovery of Potential Drugs for Cancers and Infectious Diseases
March 30, 2022
Prof. Avi Schroeder Joins SciSparc's Scientific Advisory Board to Support the Company's Development of SCI-160 for Treating Pain
March 29, 2022
SciSparc Announces Positive Results from Psychedelic-Based Pre-Clinical Trial
March 16, 2022
SciSparc Launches New JV Targeting Discovery of Potential Drugs for Cancers and Infectious Diseases
March 9, 2022
SciSparc Enters Collaboration for the Development of Innovative Psychedelic-Based Pharmaceuticals
March 7, 2022
SciSparc Presents New Leadership Lineup
January 26, 2022
SciSparc Advances Its Phase IIb Clinical Trial in Patients with Tourette Syndrome with its Proprietary Drug Candidate SCI-110
January 17, 2022
SciSparc Announces Recruitment of First Patient for its Phase IIa Clinical Trial in Alzheimer's Disease
January 5, 2022
SciSparc Issued U.S. Patent For Its Core Technology That Treats Central Nervous Systems Disorders
January 3, 2022
Decks in 2022
- Investor Presentation (February 2022)
Investor deck · 22 slides · February 2022